Becton Dickinson raised its annual adjusted profit outlook on Thursday after delivering stronger-than-expected fiscal second-quarter results driven by solid demand across its medical technology portfolio.
Shares of the company rose roughly 3% in premarket trading following the earnings release.
Adjusted earnings came in at $2.90 per share for the quarter ended March 31, exceeding analyst expectations of $2.77 per share.
Quarterly revenue reached $4.71 billion, ahead of estimates of $4.67 billion.

Drug Delivery and Surgical Segments Drive Growth

The company benefited from continued demand for pharmaceutical delivery systems, medical essentials, and surgical products.
Revenue from the interventional segment, which includes surgical solutions and advanced medical devices, increased 7.3% year over year.
Meanwhile, the medical essentials business, which includes syringes, needles, and drug-delivery devices, posted 4.7% growth.
The results suggest healthcare providers and pharmaceutical manufacturers continue increasing purchases of essential clinical and drug-administration equipment despite broader funding pressures across parts of the healthcare sector.

Annual Profit Outlook Raised

Becton Dickinson now expects full-year adjusted earnings per share between $12.52 and $12.72, raising the lower and upper ends of its prior forecast range of $12.35 to $12.65.
The company maintained its forecast for low single-digit annual revenue growth.
Management’s guidance increase reflects confidence in operational execution, improving demand stability, and contributions from core medical device businesses.

Life Sciences Industry Stabilization Emerging

The broader life sciences and healthcare tools industry continues navigating uneven demand conditions following the pandemic-era investment cycle.
While smaller biotechnology firms and academic research institutions remain cautious with spending, pharmaceutical manufacturing activity has shown signs of stabilizing.
That environment has supported demand for drug production tools, diagnostics, and medical consumables supplied by major healthcare equipment manufacturers.

Leadership Transition and Waters Deal

The company also confirmed the appointment of Vitor Roque as chief financial officer after he had served in the interim role since December 2025.
Roque has worked at Becton Dickinson for more than 25 years and helped oversee the company’s recent strategic restructuring initiatives.
Earlier this year, the company completed the spinoff and combination of its biosciences and diagnostic solutions business in a $17.5 billion transaction with Waters Corporation.
Analysts noted the stronger revenue performance and leadership stability were positive developments, although some investors continue monitoring underlying earnings quality and operating income drivers.

Outlook

Becton Dickinson’s results reinforce the resilience of essential medical technology and healthcare consumables demand despite broader uncertainty across healthcare funding markets.
Investors will continue watching margin trends, pharmaceutical manufacturing activity, and integration progress following the Waters transaction as the company moves through the remainder of 2026.